Certain aspects of the present disclosure relate to methods and systems for generating and utilizing analyte measurements. In certain aspects, a monitoring system comprises a continuous analyte sensor configured generate analyte measurements associated with analyte levels of a patient and a sensor electronics module coupled to the continuous analyte sensor and configured to receive and process the analyte measurements.

In one embodiment, an optical spectroscopy probe includes an optical fiber having a distal tip and a microfluidic filtering chamber attached to the distal tip of the optical fiber, the chamber comprising a microfluidic membrane adapted to enable liquid to enter the chamber but prevent particles from entering the chamber.

A nuclear magnetic resonance (NMR) system-based substance measurement method, including: acquiring several echo signals of an NMR pulse sequence varying in echo spacing from a substance to be measured followed by processing to obtain several signals varying in transverse relaxation and diffusion attenuation; and fitting, in combination with the prior knowledge, the signals to obtain the diffusion coefficient, transverse relaxation time or/and content weight of individual components of the substance to be measured. This application further provides a substance measurement system including a console, a magnet module, and an NMR system.

The present disclosure provides methods and devices for determining liver segments in a medical image. The methods may be implemented on the devices. The method may include: obtaining a scan image; obtaining a segmentation protocol; obtaining segmentation information associated with the scan image; determining one or more marked points based on the segmentation information and the segmentation protocol; determining one or more segmentation surfaces based on the one or more marked points; and determining a segmentation result of at least part of a liver in the scan image based on the one or more segmentation surfaces.

A device calculates a score reflecting a state of liver damage, the calculating device being designed to calculate a score using the following physical parameters: a parameter corresponding to inflammation and/or fibrosis; and a parameter corresponding to steatosis.

Systems, materials, and methods for making and using in vivo screening and highly parallel tissue grafting assay arrays are described. An implantable assay array may include a biocompatible substrate. The biocompatible substrate may define a number of mutually isolated microcompartments. The number of mutually isolated microcompartments may be determined based at least in part on a size of the implantable assay array. The size of the implantable assay array may be determined based at least in part on a size of an implantation subject.

In some embodiments, the present disclosure discloses a magnetic resonance (MR) phantom. The MR phantom includes a housing, a base medium disposed within the housing, and one or more compartment extending through the base medium, the one or more compartment comprising a crosslinked acrylamide-based polymer. The MR phantoms may be used as calibration phantoms for magnetic resonance elastography sequences and diffusion weighted images.

This method for qualitatively evaluating human livers comprises: a step (301) of computing normalized histograms of colour channels from a portion of a photograph of a liver; a step (304) of loading coefficients obtained at the end of a training phase; a step (305) of extracting from the histograms values corresponding to variables retained at the end of the training phase; a step (306) of computing a linear combination of the extracted values weighted with the loaded coefficients; and a step (308, 309) of displaying information representative of the result of the computation of the linear combination.

A method for calibration of the MRμTexture method is presented wherein a plurality of model datasets representing a continuum of structures with a continuum of biomarker values is generated by morphing data of a 2D structure or 3D structure of a first known disease state to a 2D structure or a 3D structure of a second known disease state. MRμTexture is applied in silico to extract a simulation data set of texture prevalence for a selected one of a plurality of intermediate morphed conditions corresponding to the plurality of model datasets.

A method for organ imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate or 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate. In one embodiment, the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle.